Cargando…
Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development
The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in pati...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188493/ https://www.ncbi.nlm.nih.gov/pubmed/37193682 http://dx.doi.org/10.1038/s41408-023-00815-9 |
_version_ | 1785042925348978688 |
---|---|
author | Forde, K. Cocks, K. Wells, J. R. McMillan, I. Kyriakou, C. |
author_facet | Forde, K. Cocks, K. Wells, J. R. McMillan, I. Kyriakou, C. |
author_sort | Forde, K. |
collection | PubMed |
description | The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in patients with myeloma and new combination agents are likely to impact HRQoL outcomes and its measurement. The aim of this review was to explore the use of the QLQ-MY20 and reported methodological issues. An electronic database search was conducted (1996-June 2020) to identify clinical studies/research that used the QLQ-MY20 or assessed its psychometric properties. Data were extracted from full-text publications/conference abstracts and checked by a second rater. The search returned 65 clinical and 9 psychometric validation studies. The QLQ-MY20 was used in interventional (n = 21, 32%) and observational (n = 44, 68%) studies and the publication of QLQ-MY20 data in clinical trials increased over time. Clinical studies commonly included relapsed patients with myeloma patients (n = 15, 68%) and assessed a range of combinations therapies. QLQ-MY20 subscales (disease symptoms [DS], side effects of treatment [SE], future perspectives [FP], body image [BI]) were defined as secondary (n = 12, 55%) or exploratory (n = 7, 32%) trial endpoints, particularly DS (n = 16, 72%) and SE (n = 16, 72%). Validation articles demonstrated that all domains performed well regarding internal consistency reliability (>0.7), test-reset reliability (intraclass correlation coefficient > =0.85), internal and external convergent and discriminant validity. Four articles reported a high percentage of ceiling effects in the BI subscale; all other subscales performed well regarding floor and ceiling effects. The EORTC QLQ-MY20 remains a widely used and psychometrically robust instrument. While no specific problems were identified from the published literature, qualitative interviews are ongoing to ensure new concepts and side effects are included that may arise from patients receiving novel treatments or from longer survival with multiple lines of treatment. |
format | Online Article Text |
id | pubmed-10188493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101884932023-05-18 Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development Forde, K. Cocks, K. Wells, J. R. McMillan, I. Kyriakou, C. Blood Cancer J Review Article The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in patients with myeloma and new combination agents are likely to impact HRQoL outcomes and its measurement. The aim of this review was to explore the use of the QLQ-MY20 and reported methodological issues. An electronic database search was conducted (1996-June 2020) to identify clinical studies/research that used the QLQ-MY20 or assessed its psychometric properties. Data were extracted from full-text publications/conference abstracts and checked by a second rater. The search returned 65 clinical and 9 psychometric validation studies. The QLQ-MY20 was used in interventional (n = 21, 32%) and observational (n = 44, 68%) studies and the publication of QLQ-MY20 data in clinical trials increased over time. Clinical studies commonly included relapsed patients with myeloma patients (n = 15, 68%) and assessed a range of combinations therapies. QLQ-MY20 subscales (disease symptoms [DS], side effects of treatment [SE], future perspectives [FP], body image [BI]) were defined as secondary (n = 12, 55%) or exploratory (n = 7, 32%) trial endpoints, particularly DS (n = 16, 72%) and SE (n = 16, 72%). Validation articles demonstrated that all domains performed well regarding internal consistency reliability (>0.7), test-reset reliability (intraclass correlation coefficient > =0.85), internal and external convergent and discriminant validity. Four articles reported a high percentage of ceiling effects in the BI subscale; all other subscales performed well regarding floor and ceiling effects. The EORTC QLQ-MY20 remains a widely used and psychometrically robust instrument. While no specific problems were identified from the published literature, qualitative interviews are ongoing to ensure new concepts and side effects are included that may arise from patients receiving novel treatments or from longer survival with multiple lines of treatment. Nature Publishing Group UK 2023-05-16 /pmc/articles/PMC10188493/ /pubmed/37193682 http://dx.doi.org/10.1038/s41408-023-00815-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Forde, K. Cocks, K. Wells, J. R. McMillan, I. Kyriakou, C. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development |
title | Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development |
title_full | Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development |
title_fullStr | Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development |
title_full_unstemmed | Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development |
title_short | Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development |
title_sort | use of the european organisation for research and treatment of cancer multiple myeloma module (eortc qlq-my20): a review of the literature 25 years after development |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188493/ https://www.ncbi.nlm.nih.gov/pubmed/37193682 http://dx.doi.org/10.1038/s41408-023-00815-9 |
work_keys_str_mv | AT fordek useoftheeuropeanorganisationforresearchandtreatmentofcancermultiplemyelomamoduleeortcqlqmy20areviewoftheliterature25yearsafterdevelopment AT cocksk useoftheeuropeanorganisationforresearchandtreatmentofcancermultiplemyelomamoduleeortcqlqmy20areviewoftheliterature25yearsafterdevelopment AT wellsjr useoftheeuropeanorganisationforresearchandtreatmentofcancermultiplemyelomamoduleeortcqlqmy20areviewoftheliterature25yearsafterdevelopment AT mcmillani useoftheeuropeanorganisationforresearchandtreatmentofcancermultiplemyelomamoduleeortcqlqmy20areviewoftheliterature25yearsafterdevelopment AT kyriakouc useoftheeuropeanorganisationforresearchandtreatmentofcancermultiplemyelomamoduleeortcqlqmy20areviewoftheliterature25yearsafterdevelopment AT useoftheeuropeanorganisationforresearchandtreatmentofcancermultiplemyelomamoduleeortcqlqmy20areviewoftheliterature25yearsafterdevelopment |